Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma
Journal of Veterinary Internal Medicine · 2024
DOI: 10.1111/jvim.17139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2024. Verfasst von Ashley S Parker und 4 weiteren Autor:innen. Beteiligte Einrichtung: Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA. Hauptthemen laut MEDLINE: Dog Diseases, Vincristine, Cyclophosphamide, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FDA HHS, VetDC, Inc, U.S. Food and Drug Administration.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Dogs with lymphoma that fail cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (CHOP) before completion of their protocol are commonly thought to have poor long-term outcome, but no previous studies have evaluated the effect of early relapse on progression-free interval (PFI) or overall survival time (OST) for patients undergoing rescue chemotherapy.
Objective
Correlate rescue treatment outcomes in dogs with multicentric lymphoma with outcomes after 1st-line CHOP chemotherapy.
Methods
Data were collected from 6 previous retrospective or prospective studies in 187 dogs with multicentric lymphoma that received 1st-line CHOP chemotherapy and then received either lomustine (CCNU), L-asparaginase and prednisone (LAP), or rabacfosadine (RAB, Tanovea), with or without prednisone or L-asparaginase.
Results
The PFI after initiation of CHOP chemotherapy was significantly associated with response rate postprogression, PFI, and postrescue survival time (ST) for both rescue protocols. Immunophenotype (B- vs T-cell) was not significantly associated with response, PFI or OST for LAP but was significantly associated with response and PFI for RAB.
Conclusion
Dogs that experience short PFI during or after 1st-line CHOP chemotherapy had lower response rates to rescue treatment, with shorter PFI and ST. Immunophenotype did not significantly affect outcome with LAP but was associated with PFI for RAB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.
- Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA.
- Red River Animal Emergency Hospital & Referral Center, Fargo, North Dakota, USA.
ORCID-Profile: Ashley S Parker, Jenna H Burton, Douglas H Thamm
Förderung
- FDA HHS
- VetDC, Inc
- U.S. Food and Drug Administration
- Elanco Animal Health
Zitieren
APA
Parker, A. S., Burton, J. H., Curran, K. M., Wolf-Ringwall, A., & Thamm, D. H. (2024). Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17139
Vancouver
Parker AS, Burton JH, Curran KM, Wolf-Ringwall A, Thamm DH. Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17139
BibTeX
@article{Parker2024,
author = {Parker, Ashley S and Burton, Jenna H and Curran, Kaitlin M and Wolf-Ringwall, Amber and Thamm, Douglas H},
title = {Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
doi = {10.1111/jvim.17139}
}
EUVIMED